Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Thetis Study
NCT07446439Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Nausea and Vomiting comparing Placebo Group with Tradipitant Group (2 arms). Primary endpoint: Proportion of participants with at least 1 vomiting episode per week at 1 week. Started Mar 2026; status: recruiting.
02
Drugs
tradipitant
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NCT07446439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446439.